Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program

Open access
Hivert, Marie-France, Jablonski, Kathleen A., Perreault, Leigh, Saxena, Richa, McAteer, Jarred B., Franks, Paul W., Hamman, Richard F., Kahn, Steven E., Haffner, Steven, the DIAGRAM Consortium, Meigs, James B., Altshuler, David, Knowler, William C., Florez, Jose C., for the Diabetes Prevention Program Research Group · 2011 · Diabetes

Abstract

OBJECTIVE: Over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (GRSs) developed from these loci predict diabetes in the general population. We tested if a GRS based on an updated list of 34 type 2 diabetes–associated loci predicted progression to diabetes or regression toward normal glucose regulation (NGR) in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS: We genotyped 34 type 2 diabetes–associated variants in 2,843 DPP participants at high risk of type 2 diabetes from five ethnic groups representative of the U.S. population, who had been randomized to placebo, metformin, or lifestyle intervention. We built a GRS by weighting each risk allele by its reported effect size on type 2 diabetes risk and summing these values. We tested its ability to predict diabetes incidence or regression to NGR in models adjusted for age, sex, ethnicity, waist circumference, and treatment assignment. RESULTS: In multivariate-adjusted models, the GRS was significantly associated with increased risk of progression to diabetes (hazard ratio [HR] = 1.02 per risk allele [95% CI 1.00–1.05]; P = 0.03) and a lower probability of regression to NGR (HR = 0.95 per risk allele [95% CI 0.93–0.98]; P < 0.0001). At baseline, a higher GRS was associated with a lower insulinogenic index (P < 0.001), confirming an impairment in β-cell function. We detected no significant interaction between GRS and treatment, but the lifestyle intervention was effective in the highest quartile of GRS (P < 0.0001). CONCLUSIONS: A high GRS is associated with increased risk of developing diabetes and lower probability of returning to NGR in high-risk individuals, but a lifestyle intervention attenuates this risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-1119

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Diabetes incidence rate (case subjects/100 person-year) in each GRS quartile per treatment arm adjusted for age, sex, ethnic background, and waist circumference. Although the GRS was associated with diabetes incidence in the full cohort, not all P values reached nominal statistical significance in the stratified treatment arms (PBO, P = 0.152; MET, P = 0.039; ILS, P = 0.877). In the 4th quartile of GRS: PBO vs. MET, P = 0.315; PBO vs. ILS, P < 0.0001. PBO, placebo group; MET, metformin treatment arm; ILS, intensive lifestyle treatment arm.
FIG. 1. Diabetes incidence rate (case subjects/100 person-year) in each GRS quartile per treatment arm adjusted for age, sex, ethnic background, and waist circumference. Although the GRS was associated with diabetes incidence in the full cohort, not all P values reached nominal statistical significance in the stratified treatment arms (PBO, P = 0.152; MET, P = 0.039; ILS, P = 0.877). In the 4th quartile of GRS: PBO vs. MET, P = 0.315; PBO vs. ILS, P < 0.0001. PBO, placebo group; MET, metformin treatment arm; ILS, intensive lifestyle treatment arm.CC BY-NC-ND · PubMed Central
FIG. 2. Regression rate (case subjects/100 person-year) to NGR in each GRS quartile per treatment arm adjusted for age, sex, ethnic background, and waist circumference. Although the GRS was associated with regression to NGR in the full cohort, not all P values reached nominal statistical significance in the stratified treatment arms (PBO, P = 0.123; MET, P = 0.001; ILS, P = 0.027). In the 4th quartile of GRS: PBO vs. MET, P = 0.062; PBO vs. ILS, P < 0.0001. PBO, placebo group; MET, metformin treatment arm; ILS, intensive lifestyle treatment arm.
FIG. 2. Regression rate (case subjects/100 person-year) to NGR in each GRS quartile per treatment arm adjusted for age, sex, ethnic background, and waist circumference. Although the GRS was associated with regression to NGR in the full cohort, not all P values reached nominal statistical significance in the stratified treatment arms (PBO, P = 0.123; MET, P = 0.001; ILS, P = 0.027). In the 4th quartile of GRS: PBO vs. MET, P = 0.062; PBO vs. ILS, P < 0.0001. PBO, placebo group; MET, metformin treatment arm; ILS, intensive lifestyle treatment arm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Cited by

See all 191

Metadata

Authors
Hivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, Meigs, J. B., Altshuler, D., Knowler, W. C., Florez, J. C., & for the Diabetes Prevention Program Research Group
Affiliations
  • Université de Sherbrooke (CA)
  • George Washington University (US)
  • University of Colorado Anschutz (US)
  • Broad Institute (US)
  • Lund University (SE)
  • Colorado School of Public Health (US)
  • University of Washington (US)
  • Baylor College of Medicine (US)
  • Harvard University (US)
  • National Institutes of Health (US)
  • Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts
Venue
Diabetes
Published
2011-03-22
Volume
60
Issue
4
Pages
1340-1348
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2119445047
Cited by
191
References
36
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 13 · 2020: 9 · 2019: 13 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 17 · 2014: 19 · 2013: 11 · 2012: 30
FWCI
13.57
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • Site cant be reached (submittedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK072041, K24DK080140, P30DK017047)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, polygenic risk score, Diabetes Prevention Program, diabetes incidence, lifestyle intervention, metformin, insulinogenic index, beta-cell function, genetic susceptibility
MeSH terms
Diabetes Mellitus, Type 2, Exercise Therapy, Genotype, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Metformin, Weight Loss, Polymorphism, Single Nucleotide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program. https://app.cochat.ai/papers/10.2337/db10-1119
The paper
Hivert, M.-F., Jablonski, K. A., Perreault, L., Saxena, R., McAteer, J. B., Franks, P. W., Hamman, R. F., Kahn, S. E., Haffner, S., the DIAGRAM Consortium, Meigs, J. B., Altshuler, D., Knowler, W. C., Florez, J. C., & for the Diabetes Prevention Program Research Group. (2011). Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program. Diabetes. https://doi.org/10.2337/db10-1119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.